Literature DB >> 31910940

Association between ApoE Polymorphism and Type 2 Diabetes: A Meta-Analysis of 59 Studies.

Da Wei Chen1, Ji Kang Shi2, Yun Li3, Yu Yang4, Shu Ping Ren5.   

Abstract

OBJECTIVE: To identify the important risk factors for type 2 Diabetes Mellitus (T2DM) and develop effective strategies to address the problem of T2DM. Our study aimed to evaluate the association between apolipoprotein E (ApoE) genetic polymorphism and type 2 diabetes, and to provide clues for the etiology of T2DM.
METHODS: Based on the criteria of inclusion and exclusion, we extracted, pooled, analyzed and assessed the case-control studies of ApoE polymorphism and T2DM published in PubMed, Web of Science, Medline, WanFang, VIP, and CNKI databases by R soft-ware (version 3.4.3). We used Random-effect models when heterogeneity was present in between-study, and fixed-effect models otherwise.
RESULTS: We had 59 studies covering 6,872 cases with T2DM and 8,250 controls, and compared the alleles and genotypes of ApoE between cases and controls. When we conducted a comparison between ApoE ε4 and ε3 alleles, we produced a pooled OR of 1.18 (95% CI: 1.09-1.28; P < 0.001). ApoE ε2/ε2 genotype displayed a possible association with T2DM (OR = 1.46; 95% CI: 1.11-1.93; P = 0.007), ε3/ε4 genotype showed a 1.11-fold risk (OR = 1.11; 95% CI: 1.01-1.22; P = 0.039) and ε4/ε4 genotype had a 1.71-fold risk of developing T2DM (OR = 1.71; 95% CI: 1.33-2.19; P < 0.001) when they were compared with ε3/ε3 genotype.
CONCLUSION: There is an association between ApoE polymorphism and T2DM: allele ε4 and genotypes (ε2/ε2, ε3/ε4, and ε4/ε4) are associated with the increased risk for the development of T2DM, and they may be risk factors for T2DM.
Copyright © 2019 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.

Entities:  

Keywords:  Apolipoprotein E; Meta-analysis; Polymorphism; Type 2 diabetes

Mesh:

Substances:

Year:  2019        PMID: 31910940     DOI: 10.3967/bes2019.104

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  6 in total

1.  Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank.

Authors:  Mengyu Li; Jie V Zhao; Man Ki Kwok; C Mary Schooling
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

Review 2.  Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease.

Authors:  Morteza Abyadeh; Vivek Gupta; Veer Gupta; Nitin Chitranshi; Yunqi Wu; Ardeshir Amirkhani; Anna Meyfour; Samran Sheriff; Ting Shen; Kunal Dhiman; H Salekdeh Ghasem; A Haynes Paul; L Graham Stuart; Mehdi Mirzaei
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

3.  Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes.

Authors:  Mikaël Croyal; Matthieu Wargny; Kevin Chemello; Chloé Chevalier; Valentin Blanchard; Edith Bigot-Corbel; Gilles Lambert; Cédric Le May; Samy Hadjadj; Bertrand Cariou
Journal:  Cardiovasc Diabetol       Date:  2022-02-07       Impact factor: 9.951

4.  Dissecting the Association of Apolipoprotein E Gene Polymorphisms With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Authors:  Lei Wu; Yan Zhang; Hong Zhao; Guodong Rong; Peijun Huang; Fang Wang; Ting Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-08       Impact factor: 5.555

Review 5.  Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites.

Authors:  Elizabeth M Rhea; William A Banks; Jacob Raber
Journal:  Biomedicines       Date:  2022-07-02

6.  Effects of Apolipoprotein E polymorphism on carotid intima-media thickness, incident myocardial infarction and incident stroke.

Authors:  Anitha Pitchika; Marcello Ricardo Paulista Markus; Sabine Schipf; Alexander Teumer; Sandra Van der Auwera; Matthias Nauck; Marcus Dörr; Stephan Felix; Hans-Jörgen Grabe; Henry Völzke; Till Ittermann
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.